BioCryst Pharmaceuticals, Inc. Q2 2026 Earnings Recap

BioCryst’s shares gained 3.1% following Q2 results highlighted by solid ORLADEYO revenue growth and successful pediatric launch execution, reflecting confidence in commercial momentum and operational progress.

Key Takeaways

• Total revenue rose 45% year-over-year on a comparable basis, excluding the European divestiture.
• ORLADEYO revenue increased 10% year-over-year to $158.2 million, supported by strong new patient demand and steady new prescriber additions.
• Pediatric ORLADEYO pellets launched with 47 prescriptions received through July 31, exceeding full-year expectations despite earlier manufacturing delays.
• Paid prescription rate improved slightly to 84%, up from 83% a year ago, following completion of a major reauthorization season.
• Strategic shift to end internal drug discovery to focus on external innovation aims to build a more balanced pipeline without impacting current clinical programs.